The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension.
Company Details
- Employees
- 8
- Founded
- 2018
- Address
- Innovation Centre, Norwich,nr4 7gj,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ikarovec.com
- Keywords
- gene therapy, ophthalmology, diabetic macular edema (DME), wet age-related macular degeneration, geographic atrophy, ocular hypertension.
- HQ
- Norwich
Ikarovec Questions
Ikarovec's website is http://www.ikarovec.com
Ikarovec's LinkedIn profile is https://uk.linkedin.com/company/ikarovec
Ikarovec has
8 employees.
View email and phone details for 8
employees at Ikarovec.
Ikarovec's industry is
Biotechnology Research
Ikarovec's top competitors are
Be Biopharma,
Antiverse,
Serendip Innovations,
Glyprovac,
Avencell,
Shift Bioscience,
Theriva Biologics, Inc.,
Fuse Vectors,
Atlyphe Ag,
Gene Vector.
Ikarovec's categories are Biotechnology Research
Ikarovec's founding year is 2018
